Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Belgium
/
Healthcare
/
Nyxoah
NYXH
Nyxoah
FDA And Payer Challenges Will Constrain Rollout Yet Hint Potential
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
17 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€7.00
20.6% undervalued
intrinsic discount
17 Aug
€5.56
Loading
1Y
-27.0%
7D
-23.6%
Author's Valuation
€7.0
20.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€7.0
20.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-189m
102m
2017
2019
2021
2023
2025
2027
2028
Revenue €101.9m
Earnings €4.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
50.56%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.99%
Calculation
€4.12m
Earnings '28
x
100.38x
PE Ratio '28
=
€413.61m
Market Cap '28
€413.61m
Market Cap '28
/
48.25m
No. shares '28
=
€8.57
Share Price '28
€8.57
Share Price '28
Discounted to 2025 @ 6.99% p.a.
=
€7.00
Fair Value '25
